Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 3/20 | 0.53 |
| ▸ | MME | P08473 | 6/20 | 0.46 |
| ▸ | ECE1 | P42892 | 2/20 | 0.45 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.43 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9852015 | 1.00 | TGFBR1 (0.53) | TGFBR1MMEECE1PDCD1LG2CD274 | |
| SCHEMBL29826167 | 0.96 | TGFBR1 (0.50) | TGFBR1MMEECE1PDCD1LG2CD274 | |
| SCHEMBL30390247 | 0.95 | TGFBR1 (0.49) | TGFBR1MMEECE1PDCD1LG2CD274 | |
| SCHEMBL30010888 | 0.93 | TGFBR1 (0.47) | TGFBR1MMEECE1PDCD1LG2CD274 | |
| SCHEMBL30389257 | 0.92 | MME (0.48) | TGFBR1MMEECE1PDCD1LG2CD274 | |
| SCHEMBL29517650 | 0.92 | MME (0.48) | TGFBR1MMEECE1PDCD1LG2CD274 | |
| SCHEMBL30010357 | 0.91 | ECE1 (0.49) | TGFBR1MMEECE1PDCD1LG2CD274 | |
| SCHEMBL29963242 | 0.91 | MME (0.46) | TGFBR1MMEECE1PDCD1LG2CD274 | |
| SCHEMBL29867829 | 0.91 | MME (0.47) | TGFBR1MMEECE1PDCD1LG2CD274 | |
| SCHEMBL18075525 | 0.89 | ECE1 (0.56) | TGFBR1ECE1PDCD1LG2CD274CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025038031-A1 | ENGINEERED MITOCHONDRION | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2025-02-20 | — | — | WO | claimed |
| US-20220289846-A1 | ANTIBODIES TO HUMAN PROGRAMMED DEATH RECEPTOR PD-1 | ZYDUS LIFESCIENCES LIMITED (IN) | 2022-09-15 | — | — | US | claimed |
| EP-3997126-A1 | ANTIBODIES TO HUMAN PROGRAMMED DEATH RECEPTOR PD-1 | Cadila Healthcare Limited (IN) | 2022-05-18 | — | — | EP | claimed |
| CN-114127317-A | Method of diagnosing disease | 4D制药科克有限公司 | 2022-03-01 | — | — | CN | claimed |
| CN-114032271-A | Oyster polypeptide and polypeptide powder with uric acid reducing effect as well as preparation method and application of oyster polypeptide and polypeptide powder | 浙江工业大学 | 2022-02-11 | — | — | CN | claimed |
| EP-0457314-A1 | Nutrient compositions containing peptides | CLINTEC NUTRITION COMPANY (US) | 1991-11-21 | — | — | EP | claimed |
| WO-2026107097-A1 | SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF | ENLAZA THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| EP-4713368-A1 | ANTI-CD28 ANTIBODIES AND METHODS RELATED THERETO | Adimab, LLC (US) | 2026-03-25 | — | — | EP | disclosed |
| US-12576025-B2 | Pharmaceutical parenteral composition of dual GLP1/2 agonist | ZEALAND PHARMA A/S (DK) | 2026-03-17 | — | — | US | disclosed |
| EP-4701651-A2 | CORECEPTOR CHIMERIC ANTIGEN RECEPTOR | Vanudis GmbH (DE) | 2026-03-04 | — | — | EP | disclosed |
| EP-4702049-A1 | NOVEL EGFR BINDING PROTEINS | Universität Stuttgart (DE) | 2026-03-04 | — | — | EP | disclosed |
| US-12534529-B1 | PTK7-binding proteins | SOLVE THERAPEUTICS, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| US-20260008868-A1 | 5T4-BINDING PROTEINS | SOLVE THERAPEUTICS, INC. (US) | 2026-01-08 | — | — | US | disclosed |
| EP-3982919-A1 | PHARMACEUTICAL PARENTERAL COMPOSITION OF DUAL GLP1/2 AGONIST | Zealand Pharma A/S (DK) | 2022-04-20 | — | — | EP | disclosed |
| CN-111620948-B | Antibodies to IL-33 | 南京赛新生物科技有限公司 | 2022-04-08 | — | — | CN | disclosed |
| CN-114207728-A | Prediction of side chain degradation in polymers by physics-based simulations | 杰南技术公司 | 2022-03-18 | — | — | CN | disclosed |
| US-11248209-B2 | Mature dendritic cell compositions and methods for culturing same | COIMMUNE, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| CN-114032271-A | Oyster polypeptide and polypeptide powder with uric acid reducing effect as well as preparation method and application of oyster polypeptide and polypeptide powder | 浙江工业大学 | 2022-02-11 | — | — | CN | disclosed |
| CN-113966226-A | Pharmaceutical parenteral compositions of dual GLP1/2 agonists | 西兰制药公司 | 2022-01-21 | — | — | CN | disclosed |
| CN-113966225-A | Pharmaceutical parenteral compositions of dual GLP1/2 agonists | 西兰制药公司 | 2022-01-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11248209-B2 | Mature dendritic cell compositions and methods for culturing same | CD40, CD40LG, CCR7 | TGFBR1 229/4885MME 3318/4885ECE1 3217/4885 |
| US-12576025-B2 | Pharmaceutical parenteral composition of dual GLP1/2 agonist | SLC5A2, GLP1R, SLC5A11 | TGFBR1 3093/4885MME 2515/4885ECE1 2482/4885 |
| US-12534529-B1 | PTK7-binding proteins | ROR1, FZD7, LTK | TGFBR1 184/4885MME 4292/4885ECE1 4644/4885 |
| US-20260008868-A1 | 5T4-BINDING PROTEINS | TNFSF11, TMIGD3, CTNNBL1 | TGFBR1 40/4885MME 1427/4885ECE1 3212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.